Medication info

Yuhan Three Chamber Forms Protect Injection

Prescription medicationSolutionInjection
Ingredient · strength
Glucose Monohydrate›143g / 1000mLL-Alanine›14g / 1000mLL-Arginine›12g / 1000mLGlycine›11g / 1000mLL-Histidine›3g / 1000mLL-Isoleucine›5g / 1000mLL-Leucine›7.4g / 1000mLL-Lysine Acetate›9.3g / 1000mLL-Methionine›4.3g / 1000mLL-Phenylalanine›5.1g / 1000mLL-Proline›11.2g / 1000mLL-Serine›6.5g / 1000mLTaurine›1g / 1000mLL-Threonine›4.4g / 1000mLL-Tryptophan›2g / 1000mLL-Tyrosine›0.4g / 1000mLL-Valine›6.2g / 1000mLCalcium Chloride Hydrate›0.74g / 1000mLAnhydrous Sodium Glycerophosphate›4.18g / 1000mLMagnesium Sulfate Hydrate›2.47g / 1000mLPotassium Chloride›4.48g / 1000mLSodium Acetate Hydrate›5.62g / 1000mLZinc Sulfate Heptahydrate›0.023g / 1000mLSoybean Oil›60g / 1000mLTriglycerides Medium-Chain›60g / 1000mLPurified Olive Oil›50g / 1000mLPurified Fish Oil (High Dose Omega-3 Fatty Acids)›30g / 1000mL
Manufacturer / importer
Yuhan Corporation
Appearance
This medication consists of a plastic packaging designed for intravenous fluids, divided into three chambers, with an oxygen absorber placed in between. Each inner chamber contains Dextrose solution.
Packaging
For infusion - 362 milliliters/bag [Solution A 197mL, Solution B 114mL, Solution C 51mL], For infusion - 952 milliliters/bag [Solution A 518mL, Solution B 300mL, Solution C 134mL], For infusion - 1206 milliliters/bag [Solution A 656mL, Solution B 380mL, Solution C 170mL], For infusion - 1448 milliliters/bag [Solution A 788mL, Solution B 456mL, Solution C 204mL]
Approval status
Active

MFDS item code 201908667 · Notified 2019.12.27 · Insurance code 642105612,642105613,642105614

Summary

Main use
Improvement of nutritional status by providing parenteral nutrition (calories, amino acids, fatty acids, etc.)
Who receives it
Adults · Children
Adult administration
The dose and infusion rate are determined according to the patient's ability to eliminate fat and metabolize nitrogen and glucose, and nutritional requirements. The dose should be individualized based on the patient's condition, body weight, nutritional and energy requirements, and additional oral/enteral intake. Trace elements, vitamins, electrolytes, etc. may be added depending on the patient's condition. Nitrogen requirements for maintenance of body protein depend on the patient's condition (e.g., nutritional status and catabolic stress or anabolism). Pediatric patients aged 12 years and older and adults - Patients with normal nutritional status or mild metabolic stress: 0.6-0.9 g/kg/day of amino acids (0.10-0.15 g/kg/day of nitrogen) - Patients under moderate to severe metabolic stress, regardless of nutritional imbalance: 0.9-1.6 g/kg/day of amino acids (0.15-0.25 g/kg/day of nitrogen) In very special cases (e.g., burns or pronounced anabolic state), the nitrogen dose may be higher. • Dose A daily dose of 20-40 ml/kg of this product corresponds to 0.6-1.3 g/kg of amino acids (0.10-0.20 g/kg of nitrogen) and total calories of 14-28 kcal/kg (non-protein calories of 11-22 kcal/kg)). This meets the requirements of most patients. In obese patients, the dose should be based on predicted normal body weight. • Infusion rate The infusion rate should not exceed 3.0 ml/kg per hour (equivalent to amino acids 0.10 g/kg, glucose 0.21 g/kg, and fat 0.08 g/kg). Administration over 14-24 hours is recommended. • Maximum daily dose The maximum daily dose depends on the patient's clinical condition and may vary from day to day. The recommended maximum daily dose is 40ml/kg. The recommended maximum daily dose of 40ml/kg provides amino acids 1.3 g/kg (0.20 g/kg of nitrogen), glucose 2.8g/kg, fat 1.1g/kg, and total calories of 28 kcal/kg (equivalent to 24 kcal/kg of non-protein calories). Administer by intravenous infusion through a peripheral or central vein.
Child administration
Pediatric patients aged 2-11 years: Adjust the dose regularly according to requirements, up to 40 mL/kg/day of this product. Pediatric patients aged 2-11 years: The infusion rate should not exceed 3.0 mL/kg per hour (equivalent to amino acids 0.10 g/kg, glucose 0.21 g/kg, and fat 0.08 g/kg). The recommended infusion duration is 12-24 hours. When administering the recommended maximum daily dose, administration should continue for at least 13 hours, except in special circumstances. Pediatric patients aged 2-11 years: The recommended maximum daily dose is 40mL/kg. The recommended maximum daily dose of 40 mL/kg provides amino acids 1.3 g/kg (0.2 g/kg of nitrogen), glucose 2.8 g/kg, fat 1.1 g/kg, and total calories of 28 kcal/kg (equivalent to 22 kcal/kg of non-protein calories).

Ingredients

Manufacturer
Yuhan Corporation

Efficacy & effects

Improvement of nutritional status by providing parenteral nutrition (calories, amino acids, fatty acids, etc.)

View approved original text

This medication is used to provide calories, amino acids, essential fatty acids, and omega-3 fatty acids for children over 2 years old and adults when oral or enteral nutrition is not possible or inadequate. It helps improve nutritional status and maintain body functions.

How it is given

Adult administration

The dose and infusion rate are determined according to the patient's ability to eliminate fat and metabolize nitrogen and glucose, and nutritional requirements. The dose should be individualized based on the patient's condition, body weight, nutritional and energy requirements, and additional oral/enteral intake. Trace elements, vitamins, electrolytes, etc. may be added depending on the patient's condition. Nitrogen requirements for maintenance of body protein depend on the patient's condition (e.g., nutritional status and catabolic stress or anabolism). Pediatric patients aged 12 years and older and adults - Patients with normal nutritional status or mild metabolic stress: 0.6-0.9 g/kg/day of amino acids (0.10-0.15 g/kg/day of nitrogen) - Patients under moderate to severe metabolic stress, regardless of nutritional imbalance: 0.9-1.6 g/kg/day of amino acids (0.15-0.25 g/kg/day of nitrogen) In very special cases (e.g., burns or pronounced anabolic state), the nitrogen dose may be higher. • Dose A daily dose of 20-40 ml/kg of this product corresponds to 0.6-1.3 g/kg of amino acids (0.10-0.20 g/kg of nitrogen) and total calories of 14-28 kcal/kg (non-protein calories of 11-22 kcal/kg)). This meets the requirements of most patients. In obese patients, the dose should be based on predicted normal body weight. • Infusion rate The infusion rate should not exceed 3.0 ml/kg per hour (equivalent to amino acids 0.10 g/kg, glucose 0.21 g/kg, and fat 0.08 g/kg). Administration over 14-24 hours is recommended. • Maximum daily dose The maximum daily dose depends on the patient's clinical condition and may vary from day to day. The recommended maximum daily dose is 40ml/kg. The recommended maximum daily dose of 40ml/kg provides amino acids 1.3 g/kg (0.20 g/kg of nitrogen), glucose 2.8g/kg, fat 1.1g/kg, and total calories of 28 kcal/kg (equivalent to 24 kcal/kg of non-protein calories). Administer by intravenous infusion through a peripheral or central vein.

Child administration

Pediatric patients aged 2-11 years: Adjust the dose regularly according to requirements, up to 40 mL/kg/day of this product. Pediatric patients aged 2-11 years: The infusion rate should not exceed 3.0 mL/kg per hour (equivalent to amino acids 0.10 g/kg, glucose 0.21 g/kg, and fat 0.08 g/kg). The recommended infusion duration is 12-24 hours. When administering the recommended maximum daily dose, administration should continue for at least 13 hours, except in special circumstances. Pediatric patients aged 2-11 years: The recommended maximum daily dose is 40mL/kg. The recommended maximum daily dose of 40 mL/kg provides amino acids 1.3 g/kg (0.2 g/kg of nitrogen), glucose 2.8 g/kg, fat 1.1 g/kg, and total calories of 28 kcal/kg (equivalent to 22 kcal/kg of non-protein calories).

Precautions

This medication should only be used under the direction of a physician. If symptoms of allergic reactions such as fever, chills, rash, or difficulty breathing occur during use, administration should be stopped immediately. Precipitation may occur when used with intravenous calcium-containing preparations, thus this medication and calcium preparations should not be administered simultaneously using the same infusion device, and the infusion line should be thoroughly cleaned before and after administration. Caution is required in premature or low-birth-weight infants due to the risk of increased plasma free fatty acid levels, especially in premature infants with severe respiratory diseases, where fatal cases have been reported after administering this medication. Patients with allergies to fish, eggs, soy, peanuts, or certain diseases such as severe hyperlipidemia, liver dysfunction, blood coagulation disorders, amino acid metabolism disorders, severe renal failure, acute shock, and uncontrolled hyperglycemia should not be administered this medication. In renal failure, diabetes, hepatic dysfunction, hypothyroidism, and sepsis, lipid metabolism disorders may occur, and careful administration is needed. During administration, blood triglyceride levels should be regularly monitored to ensure they do not exceed 4 mmol/L, as overdose may result in lipogenic syndromes, amino acid excess, or hyperglycemia. This medication contains soybean oil, fish oil, and egg yolk lipids, which may rarely cause allergic reactions, hence caution is advised for patients with a history of allergies. During administration, strict aseptic techniques must be followed to reduce the risk of infections, and the intravenous injection site should be checked daily for signs of thrombophlebitis or other complications. During pregnancy or breastfeeding, safety has not been established, thus it should only be administered when the therapeutic benefits outweigh the risks. In the case of overdose, the infusion rate should be immediately reduced or stopped, and treatment such as insulin administration or dialysis may be necessary.

Side effects

  • Tachycardia
  • shortness of breath
  • loss of appetite
  • nausea
  • vomiting
  • elevated plasma liver enzyme levels
  • thrombophlebitis
  • hypotension
  • hypertension
  • mild elevation of body temperature
Show 118 more
  • chills
  • headache
  • dizziness
  • anaphylactic or anaphylactoid reactions
  • skin rashes
  • urticaria
  • flushing
  • warmth
  • cold sensation
  • cyanosis
  • pallor
  • sore throat
  • back pain
  • bone pain
  • chest pain
  • back pain
  • lipodystrophy syndrome
  • hyperlipidemia
  • fever
  • fat infiltration
  • jaundice
  • hepatomegaly
  • splenomegaly
  • anemia
  • leukopenia
  • thrombocytopenia
  • blood coagulation disorders
  • hemolysis
  • reticulocytosis
  • abnormal liver function test results
  • coma
  • nausea
  • vomiting
  • chills
  • sweating
  • elevated body temperature
  • hyperglycemia
  • allergic reactions
  • constipation
  • diarrhea
  • pneumonia
  • stomatitis
  • delirium
  • dyspepsia
  • abdominal pain
  • hypoalbuminemia
  • insomnia
  • febrile neutropenia
  • general weakness
  • edema
  • urination disorders
  • hematuria
  • weight loss
  • hypoglycemia
  • hypocalcemia
  • heartburn
  • aspiration pneumonia
  • hematemesis
  • runny nose
  • extravasation at injection site
  • phlebitis
  • reaction at procedure site
  • dysuria
  • cough
  • infection
  • thromboembolism
  • bloody stools
  • vasculitis
  • skin infections
  • pulmonary edema
  • sepsis
  • Clostridium infection
  • candidiasis
  • dental disease
  • pancreatitis
  • weight gain
  • fluid overload
  • spinal cord compression
  • vaginal bleeding
  • tissue fluid retention
  • hyponatremia
  • intestinal obstruction
  • cervical cancer
  • gum bleeding
  • pharyngeal disease
  • depression
  • pressure ulcers
  • incontinence
  • urinary tract infection
  • malnutrition
  • laceration
  • gastroesophageal reflux disease
  • aspergillosis
  • oral thrush
  • neuropathic pain
  • neuropathy
  • esophagitis
  • vesicles
  • wound infections
  • upper abdominal pain
  • frequent urination
  • anxiety
  • ascites
  • abdominal discomfort
  • atelectasis
  • peripheral neuropathy
  • hiccups
  • colitis
  • leg edema
  • cerebral ischemia
  • acute renal failure
  • myalgia
  • hypersensitivity
  • exacerbation of hypertension
  • conjunctival hemorrhage
  • hemoptysis
  • sputum disease
  • voice disorders

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a sealed container to prevent air or moisture ingress. It should be kept at a cool temperature below 25 degrees and should not be frozen.

Appearance and packaging

Appearance

This medication consists of a plastic packaging designed for intravenous fluids, divided into three chambers, with an oxygen absorber placed in between. Each inner chamber contains Dextrose solution.

Package unit

For infusion - 362 milliliters/bag [Solution A 197mL, Solution B 114mL, Solution C 51mL], For infusion - 952 milliliters/bag [Solution A 518mL, Solution B 300mL, Solution C 134mL], For infusion - 1206 milliliters/bag [Solution A 656mL, Solution B 380mL, Solution C 170mL], For infusion - 1448 milliliters/bag [Solution A 788mL, Solution B 456mL, Solution C 204mL]

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.